IFN-α has been recently reported to induce proliferation of hematopoietic stem cells in mice.28 Induction of CML stem cells to exit G0 and entry into cell cycle may render them susceptible to TKIs and produce the superior results when the two agents are combined for the treatment of CML patients. The gene discussed is IFNA1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.